Polycythemia Vera (PV) in 2025: Rising Competition and Shifting Treatment Options
The treatment landscape for Polycythemia Vera (PV) in 2025 is rapidly evolving, with new therapies, uncertainties around generics, and pricing pressures reshaping the market outlook. Jakafi Generics: Will They Face Delays? Jakafi, a long-standing therapy for Polycythemia Vera, was projected to encounter generic competition after its patent expiration. However, recent indications suggest that...
0 Commenti 0 condivisioni 39 Views 0 Anteprima
Sponsorizzato